Thursday - September 24, 2026
Study Identifies Potential RAS Inhibitor-Immunotherapy Strategy for Pancreatic Cancer
September 23, 2026
BOSTON, Massachusetts, Sept. 23 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:

* * *

Study Identifies Potential RAS Inhibitor-Immunotherapy Strategy for Pancreatic Cancer

*

RESEARCH SUMMARY

Title: CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer

Publication: Cell; September 23, 2026

Dana-Farber Cancer In . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products